2,4-Dihydroxyphenylacetyl-L-asparagine

Discontinued Product

2,4-Dihydroxyphenylacetyl-L-asparagine (Cat. No. 0262) has been withdrawn from sale for commercial reasons.
Cat.No. 0262 - 2,4-Dihydroxyphenylacetyl-L-asparagine | C12H14N2O6 | CAS No. 111872-98-1
Description: Component of Joro spider toxin
Datasheet
Citations
Reviews
Literature

Biological Activity

Constituent of various spider toxins. Reported to be specific blocker of glutamate receptors.

Technical Data

M. Wt 282.25
Formula C12H14N2O6
Storage Desiccate at -20°C
CAS Number 111872-98-1
PubChem ID 3082629
InChI Key XWUFTPIDMLSXES-QMMMGPOBSA-N
Smiles OC1=CC=C(CC(N[C@@]([H])(CC(N)=O)C(O)=O)=O)C(O)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

References

References are publications that support the biological activity of the product.

Pan-Hou et al (1987) Inhibitory effect of 2,4-dihydroxyphenylacetylasparagine, a common moiety of spider toxin, on glutamate binding to rat brain synaptic membranes. Neurosci.Lett. 81 199 PMID: 2827066

Pan-Hou et al (1989) A spider toxin (JSTX) inhibits L-glutamate uptake by rat brain synaptosomes. Brain Res. 476 354 PMID: 2564797

Usherwood et al (1990) Mechanisms of neurotoxicity of low molecular weight spider toxins. Basic Science in Toxicology. Ed. G.N. Volans 569

Keywords: 2,4-Dihydroxyphenylacetyl-L-asparagine, 2,4-Dihydroxyphenylacetyl-L-asparagine supplier, Component, Joro, spider, toxin, Glutamate, mGlur, Receptors, Metabotropic, iGluR, Ionotropic, antagonists, blockers, Miscellaneous, 0262, Tocris Bioscience

Citations for 2,4-Dihydroxyphenylacetyl-L-asparagine

Citations are publications that use Tocris products.

Currently there are no citations for 2,4-Dihydroxyphenylacetyl-L-asparagine.

Reviews for 2,4-Dihydroxyphenylacetyl-L-asparagine

There are currently no reviews for this product. Be the first to review 2,4-Dihydroxyphenylacetyl-L-asparagine and earn rewards!

Have you used 2,4-Dihydroxyphenylacetyl-L-asparagine?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Pain

Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Metabotropic Glutamate Receptors

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Learning & Memory

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.